{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["1(1)"],"submitter":["Kurokawa Y"],"pubmed_abstract":["<h4>Background</h4>The standard chemotherapy regimen for gastric cancer has been established by several phase III trials. However, few studies have evaluated inter-institutional heterogeneity in randomised trials; such research may assure the generalisability of the results and also the reliability of the study group itself.<h4>Patients and methods</h4>The Japan Clinical Oncology Group (JCOG)9912 phase III trial compared irinotecan plus cisplatin and S-1 alone with fluorouracil alone for metastatic gastric cancer, and finally demonstrated the non-inferiority of S-1 alone with respect to overall survival (OS). Mixed effects models were used to evaluate outcomes of 658 patients from 22 hospitals. After adjustment for nine background factors, the heterogeneity in OS, progression-free survival"],"journal":["ESMO open"],"pagination":["e000031"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5070211"],"repository":["biostudies-literature"],"pubmed_title":["Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial."],"pmcid":["PMC5070211"],"pubmed_authors":["Ohtsu A","Mizusawa J","Nakamura K","Yamaguchi T","Kurokawa Y","Boku N","Fukuda H"],"additional_accession":[]},"is_claimable":false,"name":"Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial.","description":"<h4>Background</h4>The standard chemotherapy regimen for gastric cancer has been established by several phase III trials. However, few studies have evaluated inter-institutional heterogeneity in randomised trials; such research may assure the generalisability of the results and also the reliability of the study group itself.<h4>Patients and methods</h4>The Japan Clinical Oncology Group (JCOG)9912 phase III trial compared irinotecan plus cisplatin and S-1 alone with fluorouracil alone for metastatic gastric cancer, and finally demonstrated the non-inferiority of S-1 alone with respect to overall survival (OS). Mixed effects models were used to evaluate outcomes of 658 patients from 22 hospitals. After adjustment for nine background factors, the heterogeneity in OS, progression-free survival","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016","modification":"2025-04-26T16:24:47.477Z","creation":"2019-03-26T22:40:34Z"},"accession":"S-EPMC5070211","cross_references":{"pubmed":["27843586"],"doi":["10.1136/esmoopen-2015-000031"]}}